Next Article in Journal
Canadian Consensus Recommendations on the Management of Venous Thromboembolism in Patients with Cancer. Part 1: Prophylaxis
Previous Article in Journal
Establishing a Clinic-Based Pancreatic Cancer and Periampullary Tumour Research Registry in Quebec
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 2
10.3747/co.22.2430
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Management of egfr tki—Induced Dermatologic Adverse Events

by
B. Melosky
1,*,
N.B. Leighl
2,
J. Rothenstein
3,
R. Sangha
4,
D. Stewart
5 and
K. Papp
6
1
BC Cancer Agency, Vancouver, BC, Canada
2
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
3
R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, and Department of Oncology, Queen’s University, Kingston, ON, Canada
4
Cross Cancer Institute, Edmonton, AB, Canada
5
The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
6
Probity Medical Research, Waterloo, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(2), 123-132; https://doi.org/10.3747/co.22.2430
Submission received: 3 January 2015 / Revised: 6 February 2015 / Accepted: 8 March 2015 / Published: 1 April 2015

Abstract

Targeting the epidermal growth factor receptor (EGFR) pathway has become standard practice for the treatment of advanced non-small-cell lung cancer. Compared with chemotherapy, EGFR tyrosine kinase inhibitors (TKIS) have been associated with improved efficacy in patients with an EGFR mutation. Together with the increase in efficacy comes an adverse event (AE) profile different from that of chemotherapy. That profile includes three of the most commonly occurring dermatologic AES: acneiform rash, stomatitis, and paronychia. Currently, no randomized clinical trials have evaluated the treatments for the dermatologic AES that patients experience when taking EGFR TKIS. Based on the expert opinion of the authors, some basic strategies have been developed to manage those key dermatologic AES. Those strategies have the potential to improve patient quality of life and compliance and to prevent inappropriate dose reductions.
Keywords: non-small-cell lung cancer; adverse events; acneiform rash; paronychia; stomatitis; egfr tkis non-small-cell lung cancer; adverse events; acneiform rash; paronychia; stomatitis; egfr tkis

Share and Cite

MDPI and ACS Style

Melosky, B.; Leighl, N.B.; Rothenstein, J.; Sangha, R.; Stewart, D.; Papp, K. Management of egfr tki—Induced Dermatologic Adverse Events. Curr. Oncol. 2015, 22, 123-132. https://doi.org/10.3747/co.22.2430

AMA Style

Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfr tki—Induced Dermatologic Adverse Events. Current Oncology. 2015; 22(2):123-132. https://doi.org/10.3747/co.22.2430

Chicago/Turabian Style

Melosky, B., N.B. Leighl, J. Rothenstein, R. Sangha, D. Stewart, and K. Papp. 2015. "Management of egfr tki—Induced Dermatologic Adverse Events" Current Oncology 22, no. 2: 123-132. https://doi.org/10.3747/co.22.2430

APA Style

Melosky, B., Leighl, N. B., Rothenstein, J., Sangha, R., Stewart, D., & Papp, K. (2015). Management of egfr tki—Induced Dermatologic Adverse Events. Current Oncology, 22(2), 123-132. https://doi.org/10.3747/co.22.2430

Article Metrics

Back to TopTop